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ABSTRACT
Osteogenesis imperfecta (OI) is a genetic disorder characterized by altered bone quality and imbalanced bone remodeling, leading
to skeletal fractures that are most prominent during childhood. Treatments for OI have focused on restoring pediatric bone density
and architecture to recover functional strength and consequently reduce fragility. Though antiresorptive agents like
bisphosphonates (BPs) are currently the most common intervention for the treatment of OI, a number of studies have shown
efficacy of sclerostin antibody (SclAb) in inducing gains in bone mass and reducing fragility in OI mouse models. In this study, the
effects of the concurrent use of BP and SclAb were evaluated during bone growth in a mouse harboring an OI-causing Gly!Cys
mutation on col1a1. A single dose of antiresorptive BP facilitated the anabolic action of SclAb by increasing availability of surfaces for
new bone formation via retention of primary trabeculae that would otherwise be remodeled. Chronic effects of concurrent
administration of BP and SclAb revealed that accumulating cycles conferred synergistic gains in trabecular mass and vertebral
stiffness, suggesting a distinct advantage of both therapies combined. Cortical gains in mass and strength occurred through SclAb
alone, independent of presence of BP. In conclusion, these preclinical results support the scientific hypothesis that minimal
antiresorptive treatment can amplify the effects of SclAb during early stages of skeletal growth to further improve bone structure
and rigidity, a beneficial outcome for children with OI. © 2018 American Society for Bone and Mineral Research.
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Introduction
Osteogenesis imperfecta (OI) is a genetic bone disordercaused by collagen-related mutations resulting in type-
dependent skeletal phenotypes ranging from subclinical to lethal
severity.(1) Though these phenotypes are type-dependent, OI is
most commonly associated with low bone mass, altered bone
quality, and imbalanced bone remodeling leading to skeletal
fractures and deformities such as scoliosis, short stature, and
bowingof the longbones.(2) In thepresenceofOI, upregulationof
osteoclast activity causes a cellular imbalance that favors
resorption, resulting in thinner bones with fewer trabeculae,
both of which greatly increase fracture risk during childhood.(3)
Despite no current cure for the disease, treatments for
pediatric OI have focused on improving bone density to
promote functional strength and consequently reduce bone
fragility. Currently, antiresorptive agents from the class of
bisphosphonates (BPs) are the standard of care for pediatric OI.
Through their high affinity for calcium ions, these potent
inhibitors of bone resorption strongly bind to hydroxyapatite
bone surfaces where they can later be internalized by
osteoclasts to interrupt the resorption process.(4) Several
controlled clinical trials have established the beneficial effects
of treating pediatric OI with BP, including decreased bone
turnover and increased bonemineral density, particularly at sites
of trabecular bone.(5–11) During endochondral growth, primary
trabeculae are remodeled and converted to secondary spon-
giosa, and extended BP treatment interrupts this process, thus
retaining calcified cartilage and increasing metaphyseal mass. In
support of these studies, we and others have shown that with BP
treatment, significant improvements in trabecular number, but
not trabecular thickness are realized.(12–17) However, there
remain concerns about the long-term treatment and retention
of BPs in a growing skeleton,(18) and there remains a clinical need
for additional therapeutic strategies that can minimize BP dose
while maximizing therapeutic benefit.
Recently, sclerostin antibody (SclAb) has gained interest as an
anabolic approach for the treatment of OI.(19–24) Sclerostin,
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expressed in mature osteocytes, inhibits bone formation by
exerting antagonistic effects on Wnt signaling and downstream
osteoblast activity.(25) We have previously shown a significant
anabolic response to SclAb in an OI mouse model.(19–23) These
studies showed that treatment with a neutralizing antibody to
sclerostin stimulated bone formation in cortical and trabecular
bone, resulting in significant improvements in biomechanical
properties. Unlike BPs, SclAb led to significant improvements in
trabecular thickness. In the present study we sought to
determine whether BPs could be used to augment SclAb
efficacy by inducing retention of primary trabeculae, which
could then serve as a substrate for the anabolic actions of SclAb
to increase trabecular bone mass. We hypothesized that when
combined, these two interventions would independently target
different pathways of the bone remodeling cycle, leading to
increases in trabecular bone mass greater than when either
therapy was given alone. To accomplish this, in the present
study, we test the immediate and long-term effects of treating
rapidly growing Brtl/þ mice, harboring an OI-causing defect,
with SclAb and BP together during growth. Our knock-in mouse
model reproduces features of moderately severe Type IV OI.
Treatment of Brtl/þwith alendronate alone increased trabecular
bone mass through retention of calcified cartilage, with modest
cortical gains that did not translate directly to biomechanical
improvements.(17) Conversely, treatment of Brtl/þ with Scl-Ab
alone elicited significant gains in both trabecular and cortical
bone mass.(20) In the present study, through combination
therapy, SclAb and BP induce gains in both trabecular thickness
and number, leading to synergistic gains in trabecular bone
stiffness, suggesting a distinct advantage to combination
therapy in a growing mouse model of OI.
Materials and Methods
Animals
Wild-type (WT) and Brtl/þ mice with a mixed background of
SV129/CD-1/C57BL/6S were derived from heterozygous Brtl/þ
and WT parental strains.(26) To assess the short-term effects of
pamidronate (PAM) and SclAb combined, at 21 days of age, male
WT and Brtl/þmice received a single intraperitoneal injection of
PAM at either 0.3mg/kg or 0.625mg/kg (Sigma-Aldrich, St.
Louis, MO, USA) or saline control. These doses of PAM represent
10% and 20% of doses shown to induce trabecular retention for
20 days in mice of similar age.(13) After a 3-day latency period,
mice were randomly assigned to SclAb treatment (Scl-Ab VI,
25mg/kg; Amgen, Thousand Oaks, CA, USA) or saline groups
and injected subcutaneously twice a week for 2 weeks (through
day 34). SclAbwas chosen at a dose that consistently induced an
anabolic effect in our prior studies.(19–23) Calcein and alizarin
were administered 1 day before PAM and at day 35, respectively,
by intraperitoneal injection (30mg/kg; Sigma-Aldrich, St. Louis,
MO, USA) to visualize the growth pattern during treatment.
Short-term treatment mice (n¼ 7/group) were euthanized at
day 37. Similarly, to evaluate the long-term effects of PAM and
SclAb combined, male WT and Brtl/þ mice received two cycles
of combination therapy, repeating the treatment described
above on day 38. Calcein, alizarin, and calceinwere administered
1 day before cycle 1, 1 day before cycle 2, and at day 53,
respectively, by intraperitoneal injection (30mg/kg). Mice
(n¼ 10/group) were euthanized at day 55. A summary of the
experimental design for short-term and long-term assessment
of combination therapy is shown in Fig. 1A,B respectively. A
schematic of our proposed mechanism of action for combina-
tion therapy is shown in Fig. 1F. All protocols and procedures
were approved by the University of Michigan’s Committee on
Use and Care of Animals.
Micro–computed tomography
To determine the short and long-term effects of PAM and SclAb
on trabecular and cortical bone morphology, L5 vertebrae and
left femurs were scanned in water via micro–computed
tomography (mCT) (eXplore Locus SP; GE Healthcare Pre-Clinical
Imaging, London, ON, Canada). Scans were performed with the
source set at 80 kVp and 80mA using the Parker method of
rotation (180 degrees plus a 20-degree fan angle), 0.5-degree
increment angle, four frames averaged, and an acrylic beam
flattener with a 0.02 Al filter were used for filtration of beam
hardening artifacts. Images were reconstructed at a voxel size of
18mm, and a hydroxyapatite-mimicking phantom was used to
calibrate grayscale values for densitometry.(27)
Treatment of the growing skeleton with antiresorptive agents
induces formation of a BP-laden band reflecting retention of
primary spongiosa in the femur.(28,29) To study the short-term
combined influenceof PAMandSclAbon the femur, a 0.7-mmROI
wasplacedat this BP-induced retention regionof thedistal femur.
A second ROI was located distal to the band (closer to the growth
plate), representing bone formed subsequent to BP injection,
during SclAb treatment. A third ROI was located proximal to the
band representing a site of trabecular bone formed prior to BP
injection, but still under the influence of SclAb. A summary of the
position of these ROIs are shown in Fig. 1C. Segmentation and
binarizationof trabecularboneat these siteswasperformedusing
a local threshold adjusted at each site for optimal representation
of trabecular microarchitecture. Trabecular bone at and distal to
BP band was segmented at 1500 Hounsfield units (HU), while
trabecular bone found at the region proximal to BP band was
segmented at 1300 HU.
To understand the resulting effects from concurrent cycles of
combination therapy in the femur, a 4.5-mm ROI was placed at
the metaphysis just proximal to the growth plate and extending
through to the location of the proximal-most band of retained
trabecular bone. To isolate the effects of each administered
cyclic treatment, this full cycle ROI was broken down into
representative regions of cycle 1 (2.7mm) and cycle 2 (1.8mm).
Cycle 1 spanned from above the first BP band to right above the
second induced BP band. Cycle 2 spanned above the second
sclerotic BP band to right above the growth plate. A schematic of
the placement of these three ROIs is shown in Fig. 1D. Due to the
maturity of the bone and size of ROIs, a local auto-threshold was
used to quantify trabecular bone at these three regions.(30)
Although a retention-related band was observed in the femur
following BP treatment, a “bone in bone” appearance was
induced in the vertebral body, consistent with vertebral growth
patterns and clinical observations.(31) As a result, an ROI was
placed between the cranial and caudal endplates of the L5
vertebrae to analyze both short-term and long-term effects of
combination treatment (Fig. 1E). Vertebral cortical and trabecu-
lar bone were separated through manual contouring to denote
the outer and inner boundaries of the cortex and segmented by
a local auto-threshold.
To measure both short-term and long-term effects of treatment
on femoral cortical bone, an ROI spanning 15% of total femoral
length was centered midway between the lateral third trochanter
and the distal femoral growth plate in all samples. A local auto-
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threshold was used to quantify cortical bone. Bone architecture
parameters (trabecular number [Tb.N], trabecular thickness [Tb.Th],
bone volume fraction [BV/TV], and cortical thickness [C.Th]) were
analyzed using commercially available software (MicroView
Advanced Bone Analysis Application; GE Healthcare Pre-Clinical
Imaging, London, ON, Canada).
Bone histomorphometry
To qualitatively analyze bone formation response from short-
term and long-term combination therapy, femurs and L2
vertebrae were embedded without decalcification in methyl
methacrylate. Both tissues were sectioned longitudinally with a
Reichert-Jung Polycut microtome (Reichert-Jung, Heidelburg,
Germany) at a thickness of 8mmandmounted on gelatin-coated
glass slides. An upright microscope (Nikon Eclipse Ni-U, Tokyo,
Japan) associated with a DS-Fi2 digital camera and NIS BR
software (Nikon, Champigny-sur-Marne, France) was used to
acquire calcein and alizarin fluorescent images with a 10 dry
objective.
Biomechanical testing
To assess the mechanical effects of short-term and long-term
combination therapy, L5 vertebrae (short-term and long-term)
and left femurs (long-term only) were loaded to failure in
compression and four-point bending, respectively, using anMTS
858 Mini-Bionix servo-hydraulic testing system (MTS Systems
Corp., Eden Prairie, MN, USA). All specimens were kept hydrated
in lactated Ringer’s solution (LRS) prior to mechanical testing.
The vertebral body was vertically aligned along its loading axis
with an alignment pin (attached to lower platen and extending
through the spinal column) and compressed to failure at a
displacement rate of 0.05mm/s. For four-point bending, the
posterior surface of the femur was oriented in tension and the
mid-diaphysis was loaded to failure at a displacement rate of
0.5mm/s. Force and vertical displacements were continuously
recorded throughout each test by a 50-lb load cell (Sensotec,
Columbus, OH, USA) and an external linear variable differential
transducer (LVDT; Lucas Schavitts, Hampton, VA, USA), respec-
tively. A custom-developed LABVIEW program was used to
calculate the mechanical properties for both tissues.
Statistics
Regional variations in bone architecture and biomechanics
among the different treatments were determined using two-
way ANOVA (GraphPad Prism 6.0; GraphPad Software, Inc., La
Jolla, CA, USA) for each genotype independently. Values of
p<0.05 were considered significant, and significance is
expressed on each plot for independent effects of PAM (vertical
arrow) and SclAb (horizontal arrow) within each genotype. Data
are reported through dumbbell dot plots that display group
means of PAM treatment (white markers) and PAMþ SclAb
treatment (solid markers) for both Brtl/þ (blue and circles) and
WT (black and squares). Standard deviations are shown as
shadows behind each marker.
Results
PAM and SclAb contribute distinct gains in distal femoral
trabecular number and thickness following a single cycle
of combination therapy
At the metaphyseal band site, where BP induces the greatest
trabecular retention, PAMmonotherapy induceda significantdose-
dependent preservation of Tb.N at 0.3mg/kg (Brtl/þ 3.297
1.796/mm; WT 5.677 1.446/mm) and 0.625mg/kg (Brtl/þ
4.648 1.471/mm; WT 6.225 1.675/mm) compared to vehicle-
treated control (Brtl/þ 1.905 0.746/mm; WT 3.343 0.574/mm;
Fig. 2, Supporting Table 1). Although PAM solely acted to stabilize
Tb.N, SclAb monotherapy induced significant gains in both Tb.Th
(Brtl/þ 0.049 0.004mm; WT 0.059 0.007mm) and Tb.N (Brtl/þ
3.143 0.574mm; WT 5.272 1.349mm) compared to untreated
control (Brtl/þ 0.035 0.005mm, 1.905 0.746/mm; WT
0.037 0.003mm, 3.343 0.574/mm). When PAM and SclAb
were administered together, PAM continued to show no effect
on Tb.Th, while SclAb triggered consistent thickness gains of
Fig. 1. Combination therapy to assess the effects after (A) a single cycle and (B) concurrent cycles of combination therapy. Region of interest placement
in distal femoral metaphysis to analyze the (C) short-term, (D) long-term, and (E) vertebral trabecular bone effects of combination therapy. (F) Proposed
mechanism of action for combination therapy.
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0.049 0.008mm for Brtl/þ and 0.067 0.013mm for WT across
PAM doses. Interestingly, SclAb alone induced retention of Tb.N
comparable to that of 0.3mg/kg PAM alone (3.143 1.133/mm
versus 3.297 1.796/mm). Together, combining SclAb and PAM
during a single cycle of combination therapy contributed to a
maximum increase in bone volume fraction of 0.263 0.069 for
Brtl/þ and 0.443 0.130 for WT over untreated control (Brtl/þ
0.065 0.027; WT 0.124 0.025). Comparing regions proximal and
distal to metaphyseal band, we noted that these effects were
isolated to the site of concurrent drug administration (see
Supporting Fig. 1). Trabecular bone distal to BP site showed
minimal effect of BP as Tb.N was not significantly different from
placebo. However, SclAb induced consistent gains in Tb.Th and Tb.
N as monotherapy. At the proximal-most sites formed prior to BP
intervention,BPeffectwas less evident,while significantgains inTb.
Th and BV/TV were still observed with SclAb.
Multiple cycles helps stabilize bone mass gains from
combination treatment
Following two cycles of combination therapy (Fig. 3A, Support-
ing Table 2), in trabecular regions extending across the entire
metaphysis, PAM continued to show no effect on Tb.Th, acting
solely to further stabilize Tb.N at 0.3mg/kg (Brtl/þ
3.813 0.856/mm; WT 4.557 0.624/mm) and 0.625mg/kg
(Brtl/þ 4.329 0.863/mm; WT 5.128 0.687/mm) compared
to untreated controls (Brtl/þ 2.929 0.753/mm; WT
4.318 1.131/mm). SclAb continued to induce gains in Tb.Th
(Brtl/þ 0.050 0.004mm; WT 0.057 0.006mm), as well as a
significant preservation of Tb.N (Brtl/þ 4.899 0.595/mm; WT
5.796 0.823/mm) across all PAM doses. As a result of these
effects, maximum gains in bone volume fraction of
0.262 0.057 for Brtl/þ and 0.362 0.071 for WTwere observed
due to cumulative effects from both drugs compared to
untreated control (Brtl/þ 0.107 0.039; WT 0.189 0.067). To
further explore the effect of dose and time, the entire
metaphyseal trabecular bone ROI was subdivided into two
separate proximal and distal regions. The proximal-most region
represented cycle 1 (Fig. 3B, Supporting Table 2), and represents
the fate of the band explored in Fig. 2 following a second cycle of
therapy. During a typical course of therapy, BP will interfere with
the growth-associated trabecular modeling that would normally
cause trabeculae to gradually disappear during growth, thus
stabilizing trabecular number over time. Here (Fig. 3B, Support-
ing Table 2), Tb.N of PAM-alone animals drops below levels
shown in Fig. 2, confirming that the low dose of PAM was
insufficient to stabilize bone mass long-term. Although the low
dose of PAM was sufficient to restore Brtl/þ Tb.N to WT levels
after the first cycle, the higher dose was required for the rescue
effects to sustain throughout the second cycle. The distal-most
region chosen represented cycle 2 (Fig. 3C, Supporting Table 2),
and shows the retention band induced by the second PAM
administration in the presence or absence of SclAb. Here,
progressive gains in Tb.N are apparent, and Tb.Th gains in
response to SclAb following cycle 2 (Brtl/þ 29%: WT 28%) were
substantially less than those observed in the proximal region of
interest (Brtl/þ 53%; WT 53%), reflecting either the shorter
treatment duration for this site, or a saturation effect of SclAb on
trabecular thickness.
Multiple treatments of PAM and SclAb significantly slows
the turnover of primary spongiosa
To assess the fate of bone formed during a single treatment
cycle (Fig. 4A), calcein (green)was administered at the beginning
of PAM (or control) and alizarin (red) at the end of SclAb (or
control) treatment. Using this labeling scheme, bone formed
and retained following PAM is shown in green, while bone
formed subsequent to PAM is green. During growth, untreated
Brtl/þ control showed a significant loss of primary trabeculae,
reflected by total absence of green trabecular label (Fig. 4A, top
left). PAM alone increased preservation of trabecular bone
shown by retained spicules of calcein label (Fig. 4A, top right). In
contrast SclAb alone (Fig. 4A, bottom left) exhibited retention of
calcein label with adjacent alizarin-labeled bone, indicating
trabecular thickening on preserved primary spongiosa. Com-
bined, SclAb and PAM induced an additive bone mass response
at the site of concurrent drug administration (Fig. 4A, bottom
right). These patterns of trabecular preservation and thickening
amplify under the influence of two cycles of therapy (Fig. 4B) as
gains expand further down the proximal femur compared to
gains seen after one cycle (Fig. 4A). Significant preservation of
second-cycle Tb.N is apparent from alizarin-labeled trabeculae
in PAM-treated femurs (Fig. 4B, top right), whereas SclAb alone
led to both retention of trabeculae and thickening, indicated by
alizarin-labeled trabeculae with abundant calcein label (Fig. 4B,
bottom left). Robust gains in trabeculae and thickness are
appreciated when both drugs were given together in multiple
cycles as seen through retained alizarin-labeled trabeculae with
a calcein-labeled thickness (Fig. 4B, bottom right).
Fig. 2. mCT analysis at the site of concurrent drug administration showed that PAM induced a significant dose-dependent increase in Tb.N whereas
SclAb contributed to significant gains in both Tb.N and Tb.Th. Together these independent gains led to an additive gain in bone volume fraction with
increasing PAM doses. Results of two-way ANOVA factors: p< 0.05; p< 0.01; p< 0.001; p< 0.0001.
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Multiple cycles of combination therapy induce
synergistic gains in vertebral trabecular bone mass
Microstructural analysis of the lumbar vertebra demonstrated
similar findings, albeit to a lesser extent, as seen in the femoral
metaphysis, confirming consistency of effects at axial and
appendicular sites. Under the influence of a single treatment
cycle (Fig. 5A, Supporting Table 3), PAM monotherapy signifi-
cantly stabilized Tb.N at 0.3mg/kg (Brtl/þ 6.137 0.536/mm;
WT 6.573 0.459/mm) and 0.625mg/kg (Brtl/þ 6.376
Fig. 3. (A) Entire metaphyseal trabecular bone ROI following two cycles of combination therapy showed that PAM continued to influence Tb.N while
inducing no effects on Tb.Th. SclAb, however, induced gains in both Tb.Th and Tb.N. Each cyclic treatment was separately analyzed by subdividing the
entire metaphyseal trabecular bone ROI into (B) cycle 1 and (C) cycle 2. Isolating the effects of each administered cycle confirmed that these low doses of
PAM were weak in sustaining long-term trabeculae preservation. Results of two-way ANOVA factors: p< 0.05; p< 0.01; p< 0.001; p< 0.0001.
Fig. 4. Histological sections of Brtl/þmetaphysis revealed short-term (A) and long-term (B) bone formation activity from a single and concurrent cycles
of combination therapy, respectively. (A) At the BP-induced retention region, higher dosages of PAM were associated with greater primary trabeculae
retention (yellow), while SclAb predominantly increased thickness (red). (B) Consecutive cycles of combination therapy showed a greater robust effect on
bone mass with higher dosages of PAM. Calcein (green) was administered at the beginning and end of concurrent treatment cycles while alizarin (red)
was administered prior to the second cyclic treatment. Sections visualized represent n¼ 4 per group.
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0.569/mm; WT 6.886 0.363/mm) over placebo control (Brtl/þ
5.787 0.300/mm; WT 6.130 0.271/mm), with no effect on Tb.
Th. SclAb monotherapy produced gains in both Tb.N (Brtl/þ
6.208 0.420/mm; WT 6.816 0.376/mm) and Tb.Th (Brtl/þ
0.046 0.002mm; WT 0.053 0.004mm). As found in the femur,
when SclAb was administered with PAM, little additional gains
were observed in Tb.N. Higher doses of PAMwere required to see
additional trabecular thickening in Brtl/þ, while WT showed an
average 0.055mm increase in Tb.Th with the two drugs
combined. Despite these observations during a single cycle of
combination therapy, overall gains in BV/TV were comparable
whether drugs were given combined (Brtl/þ 0.298 0.043; WT
0.388 0.029) or SclAb alone (Brtl/þ 0.289 0.032; WT
0.365 0.040). Lumbar vertebrae benefited strongly from two
treatment cycles (Fig. 5B), triggering a maximum synergistic
response on BV/TV (Brtl/þ 0.421 0.053; WT 0.504 0.053) over
placebo (Brtl/þ 0.235 0.026; WT 0.293 0.037) compared to
0.625mg/kg PAM (Brtl/þ 0.275 0.046; WT 0.315 0.033) and
SclAb (Brtl/þ 0.339 0.043; WT 0.452 0.065) monotherapy.
PAM continued to increase bone mass through Tb.N at
0.3mg/kg (Brtl/þ 6.002 0.444/mm; WT 6.487 0.346/mm)
and at 0.625mg/kg (Brtl/þ 6.300 0.614/mm; WT
6.838 0.340/mm)with no effect on Tb.Th. SclAb induced strong
gains in both Tb.N (Brtl/þ 6.867/mm; WT 6.889/mm) and Tb.Th
(Brtl/þ 0.058 0.004mm; WT 0.070 0.007mm) across all PAM
dosages, contributing substantially to the overall synergistic
gains in lumbar vertebrae trabecular bone mass.
Substantial preservation of Tb.N and increased Tb.Th in
vertebral body
To evaluate the response of newly formed bone under the
effects of a single treatment cycle (Fig. 6A), calcein (green) was
administered prior to PAM treatment and alizarin (red) after
Fig. 5. (A) Microstructural properties of the vertebral trabecular bone reveal overall preservation of Tb.Nwith PAMand increased Tb.Thwith SclAb after a
single cycle of combination therapy. (B) Withmultiple treatment cycles, the response on Tb.N and Tb.Thwas highly amplified leading to synergistic gains
on bone mass. Results of two-way ANOVA factors: p< 0.05; p< 0.01; p< 0.001; p< 0.0001.
Fig. 6. Histological coronal sections of Brtl/þ revealed bone formation activity from a single (A) andmultiple (B) cycles of combination therapy. (A) Under
a single treatment cycle, higher dosages of PAM were associated to greater primary trabeculae retention (green), while SclAb predominantly increased
thickness and connectivity between growth plates (red). (B) Multiple treatment cycles showed an evident trabecular retention response from both PAM
and SclAb; however, SclAb also induced gains in trabecular thickness (green). Together a robust trabecular response was triggered leading to uniform
trabecular bone distribution between growth plates. Sections visualized represent n¼ 4 per group.
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SclAb treatment. Brtl/þ control showed few primary trabeculae
labeled with calcein, which was stabilized with a single dose of
PAM. SclAb showed preservation of calcein labeled bone with
alizarin labeled perimeters suggesting trabecular thickening.
These observations confirm the antiresorptive and anabolic
effects of both treatments, which led to further additive gains in
bone mass. Newly formed bone under the effects of multiple
treatment cycles (Fig. 6B), was labeled with calcein (green) at the
beginning of treatment, alizarin (red) between cyclic treatments
and again with calcein (green) at the end of treatment. Labeling
of control samples showed considerable loss of primary
trabeculae. PAM alone promoted the retention of primary
trabeculae, noted by considerable alizarin-labeled bone adja-
cent to the growth plates. SclAb alone triggered both trabecular
retention and thickness gains. Combination of both drugs
administered cyclically induced a robust trabecular response
which extended to the periosteal bone surface.
PAM intervention does not interfere with SclAb ability to
improve femoral rigidity
PAM effects were isolated to the lumbar vertebrae and femoral
trabecular bone, with no apparent effects on femoral diaphyseal
cortical bone structure or biomechanical properties. Rather, gains
in cortical thickness were solely attributed to SclAb because our
administered PAM treatment used doses significantly lower than
those used in human studies. After a single cycle of combination
therapy (Fig. 7A, Supporting Table 4), SclAbmonotherapy induced
greater gains in femoral C.Th (Brtl/þ 0.182 0.008mm; WT
0.234 0.009mm) than when combined with 0.3mg/kg PAM
(Brtl/þ 0.171 0.017mm; WT 0.234 0.009mm) or 0.625mg/kg
PAM (Brtl/þ 0.176 0.012mm; WT 0.216 0.028mm) compared
to placebo (Brtl/þ 0.152 0.016mm; WT 0.192 0.022mm).
However, this effect was transient, because after two cycles
(Fig. 7B), consistent C.Th gains of 0.231 0.023mm in Brtl/þ and
0.277 0.023mm in WT were observed across all PAM doses. As a
result of these C.Th changes, SclAb consistently improved femoral
rigidity through gains in stiffness (Brtl/þ 231.768 44.278N/mm;
WT 272.632 57.425N/mm) and ultimate load (Brtl/þ
35.379 6.741N; WT 47.816 9.937N) across all PAM doses,
drivenbygains inbendingmoment (Brtl/þ 0.158 0.045mm4;WT
0.207 0.028mm4) and cross-sectional area (Brtl/þ 1.919 0.200
mm2; WT 2.234 0.267mm2) as seen in Fig. 7C.
PAM and SclAb synergistically improve Brtl/þ vertebral
stiffness over monotherapy effects
Similar to the cortical effects seen in the femur, C.Th gains in the
vertebral bodywere influenced by SclAb, not PAM. A single cycle
of combination therapy (Fig. 8A, Supporting Table 5) resulted in
lower gains in C.Th at 0.3mg/kg (Brtl/þ 0.086 0.007mm; WT
0.102 0.006mm) and 0.625mg/kg (Brtl/þ 0.088 0.007mm;
WT 0.102 0.007mm) than SclAb monotherapy (Brtl/þ
0.091 0.005mm; WT 0.100 0.005mm). However, with
multiple cycles (Fig. 8B), greater gains in C.Th were achieved
at 0.3mg/kg (Brtl/þ 0.090 0.006mm; WT 0.103 0.010mm)
and 0.625mg/kg (Brtl/þ 0.093 0.009mm; WT
0.106 0.008mm). Functionally, over a single cycle of therapy
(Fig. 8C), PAM dose-dependently improved vertebral stiffness
and SclAb amplified this response (Brtl/þ 29%, WT 32%).
Improvements in ultimate load were attributed to SclAb with
gains of 48% in Brtl/þ and 58% in WT. Over two cycles of
combination treatment (Fig. 8D), maximum gains in vertebral
stiffness were observed when both PAM (Brtl/þ
75.650 8.031N/mm; WT 119.729 24.514N/mm) and SclAb
(Brtl/þ 81.307 15.531N/mm; WT 136.688 16.367N/mm)
were administered alone. When administered together in
sequential cycles, WT showed maximum additive gains
(156.340 28.962N/mm) compared to each treatment alone.
Remarkably, a synergistic response was observed in Brtl/þ, with
a maximum stiffness increase of 130.945 25.920N/mm
compared to placebo control (46.974 20.181N/mm).
Fig. 7. (A) Femoral cortical analysis revealed SclAb influence on C.Th varies in the presence of PAM after a single treatment cycle. (B) Following
subsequent cycles of combination therapy, C.Th nearly doubled solely in response to SclAb. (C) Functionally, multiple cycles PAM and SclAb led to
additive gains in femoral stiffness and ultimate load with progressive PAM doses. Results of two-way ANOVA factors: p< 0.05; p< 0.01; p< 0.001;
p< 0.0001.
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Discussion
The results in this study show Brtl/þmice with a genetic knock-
in for moderately severe Type IV OI responded favorably to
repeated cycles of a single dose of antiresorptive PAM in
combination with anabolic SclAb. The immediate effects of this
combination therapy showed that both interventions stimu-
lated gains in bone mass through different means, leading to
overall improvements in biomechanical function. Although a
preservation of Tb.N was observed through PAM, SclAb led to
gains in both Tb.N and Tb.Th, as well as a significant cortical
bone response. When this combination therapy was adminis-
tered twice cyclically, the resulting gains in trabecular bonemass
were dependent on anatomic site; cumulative for long bones
and synergistic for the vertebral body. These findingsmay have a
strong clinical utility to increase bone mass in OI patients—
particularly those with excessive high bone turnover leading to
severe trabecular osteopenia that might make them more
resistant to anabolic therapy alone.
Antiresorptive BPs continue to be the most common
intervention used in pediatric OI. Numerous studies have shown
a favorable bone response to BP therapy in both preclinical
studies using OI mouse models(12,17,32,33) and clinical studies of
children with OI.(7,9,33–37) By their antiresorptive activity, BPs
have been proposed to decrease the high bone turnover
characteristic of OI, increase metaphyseal bone mass by
increasing trabecular number, and increase cortical bone
mass by inhibiting endosteal resorption. However, concern for
long half-life,(38) microdamage accumulation,(39) and delayed
healing(40) have led to attempts to minimize treatment dose.(18)
Recently, SclAb has gained interest as a promising anabolic
approach for the treatment of OI. In contrast to BP, SclAb has
been shown to increase trabecular bone mass in OI models
through trabecular thickening, and increase cortical bone mass
through periosteal apposition.(19,20,22) Furthermore, in a grow-
ing model, periosteal apposition will occur as a result of growth,
which contributes to further bone mass gains because PAM has
not been shown to affect non-remodeling surfaces. Therefore,
we hypothesized that a combination of these two agents may
lead to additive if not synergistic structural and functional gains.
When given together, we observed that BPs induce retention of
primary trabeculae, which can serve as a substrate for the
subsequent anabolic response of SclAb, whereas cortical bone
mass gains resulted from SclAb alone.
Combination effects have been explored with BP following
SclAb in order to preserve gains in bone mass following
cessation of drug clinically(41) and in OI models.(23) Alternatively,
SclAb following BP has been explored using ovariectomized rats
inwhich SclAb induced gains in bonemass regardless of prior BP
exposure.(42) This study was performed in aged, osteoporotic
rats, which have considerably different growth plate dynamics
than in the present study. In another OI mousemodel, SclAbwas
combined with zoledronic acid,(43) where no synergistic effects
were observed. Rather, the treatment effect from zoledronic acid
alone led to >300% gains in proximal tibial trabecular bone
volume fraction, with no additional gains observed when
zoledronic acid was combined with SclAb. In the present
combination study, we likely avoided this saturation response
with lower doses of BP, triggering more modest trabecular
preservation, allowing SclAb to synergistically increase bone
mass by increasing trabecular thickness.
The present study differs from these other combination
therapy studies because we aimed to explore low doses of PAM
which, if given alone, would be insufficient to generate long-
term preservation of trabecular bone. Indeed, when tracking the
fate of the trabecular bone generated by the first cycle of PAM,
we observed a lack of long-term antiresorptive effects,
particularly in the vertebrae. Yet when administered together
with SclAb, both drugs combined led to cumulative gains on
bone mass. At the site of concurrent treatment, PAM induced a
sclerotic metaphyseal band consistent with previous observa-
tions of BP treatment stabilizing primary spongiosa near the
Fig. 8. (A) Vertebral cortical analysis revealed that after a single cycle, SclAb triggered greater gains in C.Th thanwhen combinedwith PAM. (B) Following
two cycles, however, consistent gains in C.Thwere observed across all PAMdosages. (C) Functionally, following a single combination cycle, PAM effect on
trabecular preservation helped improve vertebral stiffness while SclAb amplified these effects. Significant improvements in ultimate load were solely
attributed to SclAb. (D) Both drugs improved ultimate load through an additive response, however, induced a synergistic effect on vertebral stiffness
following multiple cycles of combination treatment. Results of two-way ANOVA factors: p< 0.05; p< 0.01; p< 0.001; p< 0.0001.
Journal of Bone and Mineral Research LOW DOSE BP ENHANCES SCLAB-INDUCED TRABECULAR GAINS IN OI MOUSE 1279
growth plate.(44) Treatmentwith PAM alone showed a significant
effect on bone volume fraction for both Brtl/þ and WT when
compared to untreated controls, solely due to a significant dose-
dependent preservation of Tb.Nwith no concurrent effect on Tb.
Th. Similar gains in bone volume were triggered with SclAb
monotherapy; however, these were attributed to an effect on
both Tb.N and Tb.Th. Gains in Tb.Th likely resulted from a direct
anabolic effect on existing trabecular bone. However, gains in
Tb.N could have resulted from either stabilization of thin
trabeculae destined for remodeling via increased bone forma-
tion on those surfaces, or through a mild antiresorptive effect,
because SclAb has been shown to have both anabolic and
anticatabolic actions.(45) Indeed, SclAb alone preserved Tb.N to
levels equivalent to low-dose PAM, suggesting a similar potency
of antiresorptive action between the two drugs. When given
together, extended gains in trabecular bone mass were
attributed to SclAb-induced trabecular thickening at sites
formed following PAM exposure and retention of trabecular
number. These observations were confirmed through histo-
morphometry. Observations at sites distal and proximal to the
metaphyseal band helped verify that PAM bone response was
constrained to its induced sclerotic band, while SclAb led to
trabecular thickening away from these sites.
The same trabecular response was observed in the vertebral
body for both Brtl/þ and WT, to a slightly greater extent, as was
observed in the femoral metaphysis. These findings are
consistent with other BP studies that show a variable BP
binding and bone density response between axial versus
appendicular, and cortical versus trabecular sites.(29,46) Follow-
ing two cycles of combination therapy, a synergistic effect on
bone mass was observed in the vertebral body that was not
observed in the femoral metaphysis, which instead showed an
additive effect of the two interventions. Histomorphometry of
two cycles of combination therapy demonstrated thickened
bands of retained primary spongiosa emerging from both
growth plates of the vertebra consistent observations in other
pediatric BP studies.(31,47,48)
In addition to trabecular effects, SclAb induced an anabolic
response in femoral and vertebral cortical bone, because gains
observed were solely attributed to SclAb, even when adminis-
tered in combinationwith PAM. This increase in cortical thickness
correlates with previous findings where growing Brtl/þ mice
treated with SclAb showed cortical thickness gains in the femoral
midshaft over a similar treatment duration.(20) Furthermore,
progressive gains in cortical thickness were observed comparing
one versus two cycles of SclAb monotherapy. Although clinical
studies of children with OI have shown slight changes in cortical
bone from PAM treatment,(17,49–51) in the present study, PAMhad
no effect on cortical thickness, likely due to the low treatment
duration and doses used in the present study compared to those
in clinical trials. Low doses of PAM were deliberately chosen for
this study in order to minimize the antiresorptive effect and not
mask the potential combination effects hypothesized from both
drugs together.
Two cycles of PAMmonotherapy showed no effect on femoral
stiffness or load in either Brtl/þ and WT. SclAb, on the other
hand, improved both stiffness and load as a result of the strong
anabolic effect on cortical bone. When both drugs were
administered concurrently, SclAb continued to be the sole
contributor to these improvements in whole-bone mechanical
properties.
Similarly, in the vertebral body, Brtl/þ ultimate load was only
improved by SclAb, yet both PAM and SclAb led to strong gains
in vertebral stiffness. In fact, following two cycles of combined
treatment, Brtl/þ stiffness improved synergistically when
compared to combined effects from monotherapy of either
drug. This finding may have important implications for
treatment of spinal deformities in OI. Deformation of the spine
arises from both anatomical and functional factors resulting
from the OI phenotype. Depending on the severity of the
deformity or fracture frequency, prophylactic interventions like
BP treatment can potentially reduce fracture incidence.
Combining SclAb with PAM stabilized vertebral trabecular
bone resulting in significant gains in vertebral stiffness. SclAb
alone improved maximum load, likely due to additional gains in
cortical thickness that were not evident following PAM. These
findings confirm other studies that have shown that C.Th is a
primary determinant feature for compressive strength of the
whole vertebral body.(52–54)
This study has several limitations. Because OI is a disease of
many mutations, the results of this study may not extend to all
types of OI. Additionally, the Brtl/þmouse fragility phenotype is
of moderate severity, and the mouse does not suffer spontane-
ous fractures. In addition, the study was only performed in male
mice and it is now well established that gender can affect the
outcome of drug treatments. Furthermore, BP action when
given after closure of the growth plate during skeletal maturity
will not yield the same findings as observed in this study
because turnover of primary spongiosa will be nonexistent. In
many of our outcomes, treatment with our lowest PAM dose
alone improved bone mass to WT control levels, effectively
rescuing the phenotype, while our higher PAM dose induced
gains in bone mass greater than WT baseline. Although our goal
was not to directly titrate our treatment outcomes to match
untreated WT levels, we believe that further adjustment of
treatment doses and/or duration will vary depending on clinical
severity to best represent a “rescue” response.
SclAb has been proposed as a novel anabolic intervention to
treat the low bone mass and fragility phenotype present in
patients with OI. The results in this study extend our previous
observations of single-drug therapy in Brtl/þ(17,20) and show the
benefits of combining SclAb with antiresorptive treatment
during growth. In severe cases of OI, where extreme low bone
mass may result from excessive resorption of primary trabeculae
during endochondral growth, SclAb alone might not be enough
to significantly improve trabecular bone volume because of lack
of bone upon which to exert an anabolic action. Thus, in cases of
extreme low bone mass, concurrent antiresorptive and anabolic
therapy might further improve bone formation outcomes.
Importantly, these results suggest that modest doses of BP,
which would otherwise not induce a sustained therapeutic
effect, may be sufficient to preserve trabecular architecture
enough to permit an anabolic action of SclAb on bone which
would otherwise be remodeled. Together, these preclinical
results support the scientific premise that antiresorptive and
anabolic combination therapy during early stages of skeletal
growth can help induce greater gains in bone mass in OI than
either drug alone. The present data provides key preclinical
results to support a treatment plan to maximize combination
therapy in OI, or other diseases associated with low bone mass
during pediatric growth and development.
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